SecBot SecBot
Biotech Drug Report Generated Nov 5, 2026

tenumomeran

BNTX·BioNTech SE
BEARISH
Drug Impact Rating4/10
Trial phase
Phase 2/3 (pivotal)
Time to market
If the OS readout is positive, a regulatory filing could follow in 2027-2028. If OS also misses, the program is likely terminated for this indication.
Why 4/10
The next hard catalyst is the overall survival (OS) readout from the AHEAD-MERIT Phase 2/3 trial, but no specific date has been announced. The PFS endpoint was already missed on October 13, 2026, so the binary event has passed. BNT113 is one of several late-stage oncology assets at a company with a EUR 16.2 billion cash position, so it is not a make-or-break drug.
Actionable Insight BEARISH

The next catalyst is the overall survival (OS) readout from the AHEAD-MERIT trial, which has no announced date. If OS is positive, it could salvage the program despite the PFS miss; if OS also misses, BNT113 is effectively dead for this indication. Watch for BioNTech's disclosures on the timing of the OS analysis.

Price Chart

Loading chart...

Executive Summary

Tenumomeran/raplemomeran (BNT113) is BioNTech's mRNA-based therapeutic cancer vaccine targeting HPV16-positive head and neck squamous cell carcinoma (HNSCC). On October 13, 2026, the Phase 2/3 AHEAD-MERIT trial failed its first dual primary endpoint of progression-free survival (PFS) for BNT113 plus pembrolizumab versus pembrolizumab alone. The Independent Data Monitoring Committee recommended continuing the trial to evaluate the second primary endpoint of overall survival (OS), which remains the next binary catalyst with no announced date. BioNTech has a diversified late-stage oncology pipeline and a EUR 16.2 billion cash position, so BNT113 is not a company-threatening asset, but the PFS miss significantly dented analyst confidence in the program.

How It Works

Tenumomeran/raplemomeran (BNT113) is an mRNA-based therapeutic cancer vaccine. It delivers genetic instructions (mRNA) that teach the patient's own cells to produce two proteins (E6 and E7) found on HPV16-positive cancer cells. This trains the immune system to recognize and attack tumors expressing those proteins. It is given intravenously and is designed to work alongside checkpoint inhibitor drugs like pembrolizumab (Keytruda).

Trial Status

The AHEAD-MERIT trial (NCT04534205) is a Phase 2/3 study of BNT113 plus pembrolizumab vs. pembrolizumab alone in first-line unresectable recurrent or metastatic HPV16-positive HNSCC. The Phase 3 portion's first dual primary endpoint (PFS) was missed on October 13, 2026. The trial continues to follow patients for the second dual primary endpoint of overall survival (OS).

The Two-Sided Case

▲ Bull Case4
The Independent Data Monitoring Committee recommended continuing the trial to evaluate overall survival, meaning the OS endpoint remains a viable path to a positive trial.
Precedents exist for cancer immunotherapies that improved OS after failing to extend PFS, as noted by Fierce Biotech.
BNT113 received FDA Fast Track designation in January 2026 based on preliminary AHEAD-MERIT data, signaling some regulatory interest.
BioNTech has a EUR 16.2 billion cash position (per Q3 2026 earnings) and a broad oncology pipeline, so BNT113's failure would not threaten the company's viability.
▼ Bear Case4
The Phase 3 portion of AHEAD-MERIT failed its first dual primary endpoint of progression-free survival (PFS) on October 13, 2026, with no hazard ratio or effect size disclosed, raising doubts about the drug's efficacy.
Analysts became 'significantly' less confident that BNT113 will extend overall survival after the PFS miss, per Fierce Biotech reporting.
The PFS miss is BioNTech's third mRNA cancer immunotherapy setback, adding to a pattern of disappointing results in the space.
Even if OS is positive, the bar for regulatory approval after a PFS miss is higher, and the FDA Fast Track designation does not guarantee accelerated approval.

Upcoming Catalysts

  • Overall survival (OS) readout from AHEAD-MERIT Phase 2/3 trial (no date announced)
  • Potential regulatory filing if OS is positive

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BioNTech SE 6-K BNTX ·Originating report

Sources · 14

Hover a chip for the title
1 biontech.com2 fiercebiotech.com3 onclive.com4 pharmaphorum.com5 allsci.com6 cancernetwork.com7 marketchameleon.com8 biontech.com9 biospace.com10 targetedonc.com11 ventureatlas.org12 ddw-online.com13 morningglorysciences.com14 americapharmatoday.com